Summit Partners has hired Ricardo Gonzalez as a partner on the firm’s growth products and services team.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for more North Dakotans.

Telehealth brand Hims & Hers donated $1 million to President-elect Donald Trump's inaugural committee, the company told Axios ...

As kids are still reeling from their extra snow day, parents are not happy with the Lorain School District for their ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...